Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Cardiology, Da Qing First Hospital, Da Qing, China.
Br J Cancer. 2022 Jul;127(1):102-108. doi: 10.1038/s41416-022-01758-x. Epub 2022 Mar 7.
BACKGROUND: We aimed to explore if hyperglycaemia and hyperinsulinemia in the diabetes and prediabetes population were associated with increased risk of cancer occurence. METHODS: Overall, 1700 participants with different glycaemic statuses were screened from the 110,660 residents of Da-Qing, China, in 1985. They were followed up to 30 years to access cancer outcomes. RESULTS: Cancer was identified in 15.2% (259/1700) of the participants. The incidence of cancer in the normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and diabetes groups was 6.06, 6.77, and 7.18 per 1000 person-years, respectively (P = 0.02). In the Fine-Gray model with all cause death as competing risk, compared with the NGT controls, both IGT and diabetes groups demonstrated significantly higher risk of cancer (for the IGT group, adjusted hazard ratio (aHR) = 1.77, 95% CI 1.38-2.27, P < 0.0001; for the diabetes, aHR = 3.34, 95% CI 2.64-4.22, P < 0.0001). Among the IGT participants, progress to diabetes (aHR = 2.28, 95%CI 1.24-4.20, P = 0.008) and insulin-area under the curve at baseline (for 1 SD increase, aHR = 1.39, P = 0.02) were also associated with the risk of cancer after adjustment of covariables. CONCLUSIONS: Hyperglycaemia in patients with diabetes, hyperinsulinemia, and progression to diabetes in people with IGT is significantly associated with the long-term increased risk of cancer occurrence.
背景:本研究旨在探讨糖尿病和糖尿病前期人群中的高血糖和高胰岛素血症是否与癌症发生风险增加相关。
方法:1985 年,在中国大庆的 110660 名居民中筛选出不同血糖状态的 1700 名参与者。对他们进行了长达 30 年的随访,以了解癌症结局。
结果:在 1700 名参与者中,有 15.2%(259/1700)被确诊患有癌症。在正常糖耐量(NGT)、糖耐量受损(IGT)和糖尿病组中,癌症的发生率分别为 6.06、6.77 和 7.18/1000 人年(P=0.02)。在 Fine-Gray 模型中,以全因死亡为竞争风险,与 NGT 对照组相比,IGT 和糖尿病组的癌症风险均显著升高(IGT 组校正后的危险比(aHR)=1.77,95%CI 1.38-2.27,P<0.0001;糖尿病组 aHR=3.34,95%CI 2.64-4.22,P<0.0001)。在 IGT 参与者中,进展为糖尿病(aHR=2.28,95%CI 1.24-4.20,P=0.008)和基线时胰岛素曲线下面积(增加 1SD,aHR=1.39,P=0.02)也与调整协变量后的癌症风险相关。
结论:糖尿病患者的高血糖、高胰岛素血症以及 IGT 患者进展为糖尿病与癌症发生的长期风险增加显著相关。
Lancet Diabetes Endocrinol. 2019-2-22
J Assoc Physicians India. 2007-12
Front Endocrinol (Lausanne). 2023
Cancer Immunol Immunother. 2023-10
Diabetol Metab Syndr. 2023-3-30